Havrix Junior Monodose (Hepatitis A Virus (Inactivated), Aluminium Hydroxide)

Havrix Junior Monodose is indicated for the prevention of hepatitis A infection in pediatric populations.

• Primary prophylaxis against hepatitis A in children and adolescents.
• Administration as part of a two‑dose series, with the second dose given 6–12 months after the first.
• Use in travelers from endemic regions who are younger than 18 years.
• Inclusion in national childhood immunisation programmes where hepatitis A is endemic or risk is high.

The safety profile of Havrix Junior Monodose reflects typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever occurring within 24–48 hours.
• Headache or fatigue lasting a day or two.
• Transient muscle aches.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome, though extremely rare.

Before administering Havrix Junior Monodose, health professionals should review the following precautionary considerations.

• Confirm that the child has no known severe allergy to any vaccine component, especially aluminium salts.
• Defer vaccination in individuals with a current moderate or severe acute illness.
• Assess for a history of hypersensitivity to previous hepatitis A vaccine doses.
• Consider postponing the dose in children with a weakened immune system until medically appropriate.
• Observe the patient for at least 15 minutes after injection for any immediate adverse reaction.

Havrix Junior Monodose does not have many documented drug interactions, but certain situations warrant attention.

Avoid

• Concurrent administration of other live vaccines at the same anatomical site.
• Use of immunosuppressive therapy that may diminish vaccine response.

Use with caution

• Simultaneous receipt of other inactivated vaccines; spacing may be advised per local guidelines.
• Administration in patients receiving high‑dose corticosteroids; monitor antibody response.
• Co‑administration with blood products; consider timing to avoid interference with immunogenicity.